Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Europe Lyophilized Injectable Drugs Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Aug 2021 | Europe | 350 Pages | No of Tables: 326 | No of Figures: 48

Report Description

Europe Lyophilized Injectable Drugs Market, By Packaging (Vials, Dual-Chamber Syringes, Dual-Chamber Cartridges and Others), Drug Class (Anti-Infectives, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, Corticosteroids and Others), Form (Powder and Liquid), Indication (Oncology, Autoimmune Diseases, Hormonal Disorders, Respiratory Diseases, Gastrointestinal Disorders, Dermatological Disorders, Ophthalmic Diseases and  Others), Route of Administration (Intravenous/Infusion, Intramuscular and Others), End User (Hospital, Clinics,  Home Healthcare and  Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Europe Lyophilized Injectable Drugs Market

The lyophilized injectable drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.3% in the forecast period of 2021 to 2028 and is expected to reach USD 1,612.86 million by 2028. Increase in chronic health conditions across the globe is expected to act as a driver for boosting the demand of the lyophilized injectable drugs market.

Freeze-drying is another term for lyophilization. It is a technique of isolating a solid material from a solvent by freezing and evaporating the solution under vacuum. Lyophilized products are considered to have a longer shelf life than conventional medications and are thus favoured. The protection of biologics, proteins, antibodies microorganisms, parenteral, blood plasma, enzymes, diagnostic reagents, vaccines and nutraceuticals are usually done through lyophilization. To keep some unstable bulk ingredients stable, lyophilization of the sterile injectable is needed.

Growing technological advancement of the lyophilized injectable drugs is expected to act as a driver for boosting the demand of the lyophilized injectable drugs market. Rise in number of product recalls for lyophilized drugs and packaging type is expected to act as restraint of the lyophilized injectable drugs market. Rise in regulatory approvals for lyophilized drugs is expected to act as an opportunity for boosting the demand of the lyophilized injectable drugs market. The factors associated with manufacturing lyophilized vials for parenteral products are expected to challenge the demand for the lyophilized injectable drugs market.

The lyophilized injectable drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the lyophilized injectable drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Lyophilized Injectable Drugs Market Scope and Market Size

The lyophilized injectable drugs market is categorized into seven notable segments which are based on the packaging, drug class, form, indication, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of packaging, the lyophilized injectable drugs market is segmented into vials, dual-chamber syringes, dual-chamber cartridges and others. In 2021, vials segment is expected to dominate the lyophilized injectable drugs market because most of the lyophilized injectable drugs are packaged in vials, so it is influential as well as growing in the market.
  • On the basis of drug class, the lyophilized injectable drugs market is segmented into anti-infectives, antineoplastic, diuretics, proton pump inhibitor, anesthetic, anticoagulant, NSAID’s, corticosteroids and others. In 2021, anti-infectives segment is expected to dominate the lyophilized injectable drugs market because of the increased demand for the antibiotics and antiviral drugs across globe.
  • On the basis of form, the lyophilized injectable drugs market is segmented into powder and liquid. In 2021, powder segment is expected to dominate the lyophilized injectable drugs market because of its easy and safe storage plus transportation across globe.
  • On the basis of indication, the lyophilized injectable drugs market is segmented into oncology, autoimmune diseases, hormonal disorders, respiratory diseases, gastrointestinal disorders, dermatological disorders, ophthalmic diseases and others. In 2021, oncology segment is expected to dominate the lyophilized injectable drugs market because of the availability of increased number of lyophilized injectable drugs for oncology.
  • On the basis of route of administration, the lyophilized injectable drugs market is segmented into intravenous/infusion, intramuscular and others. In 2021, intravenous/infusion segment is expected to dominate the lyophilized injectable drugs market because of the 100% bioavailability of the drug via this route of administration.
  • On the basis of end user, the lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market due to the financial capabilities of hospitals to purchase luxurious equipment along with the presence of trained professionals to administer them.
  • On the basis of distribution channel, the lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market because most of the service providers buy the lyophilized injectable drugs from manufacturers and it is noticed that revenue from direct sales is higher, so it is influential as well as growing in the market.

Get Exclusive Sample Copy of this Report Here

Europe Lyophilized Injectable Drugs Market Country Level Analysis

Europe lyophilized injectable drugs market is analysed and market size information is provided by the country, packaging, drug class, form, indication, route of administration, end user and distribution channel as referenced above.

The countries covered in the Europe lyophilized injectable drugs market are the Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe.

Vials segment in Germany is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of technological advancements and rising product approval by EMA. France is expected to occupy the second most position in market due to increase in geriatric population with chronic diseases. The vials segment in the U.K. is dominating the European market owing to high demand of safe transit and storage of drugs until their end-use.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. 

New Product Launches by manufacturers is creating new opportunities for players in the lyophilized injectable drugs market

The lyophilized injectable drugs market also provides you with detailed market analysis for every country growth in lyophilized injectable drugs industry with lyophilized injectable drugs market sales, impact of advancement in the lyophilized injectable drugs market and changes in regulatory scenarios with their support for the lyophilized injectable drugs market. The data is available for historic period 2010 to 2019. 

Competitive Landscape and Lyophilized Injectable Drugs Market Share Analysis

The lyophilized injectable drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe lyophilized injectable drugs market.

The major companies covered in the Europe lyophilized injectable drugs market report are Genex Pharma, Aristopharma Ltd., Amneal Pharmaceuticals LLC, Fresenius Kabi Ltd (a subsidiary of Fresenius Kabi AG), Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Novartis AG, Otsuka Pharmaceuticals Co., Ltd. (a subsidiary of Otsuka Holdings Co., Ltd.), Cipla Inc., Cirondrugs, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Sanofi, Celon Laboratories Pvt. Ltd. and Baxter among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies’ worldwide which are also accelerating the lyophilized injectable drugs market.

  • In November 2019, Pfizer Inc. announced that its division, named Upjohn is combined with Mylan N.V. and formed a new company named Viatris Inc. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the lyophilized injectable drugs market which also provides the benefit for organisation to improve their offering for lyophilized injectable drugs market.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PACKAGING LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN CHRONIC HEALTH CONDITIONS

6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE

6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES

6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS

6.1.5 TECHNOLOGICAL ADVANCEMENTS

6.2 RESTRAINTS

6.2.1 RISK OF NEEDLESTICK INJURIES

6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE

6.3 OPPORTUNITIES

6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS

6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS

6.3.3 QUALITY CONCERNS

6.4 CHALLENGES

6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS

6.4.2 TIME-CONSUMING PROCESS AND HIGH COST

7 IMPACT OF COVID-19 ON THE EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT IN DEMAND

7.3 IMPACT ON SUPPLY

7.4 STRATEGIC INITIATIVE

7.5 CONCLUSION

8 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING

8.1 OVERVIEW

8.2 VIALS

8.3 DUAL-CHAMBER SYRINGES

8.4 DUAL-CHAMBER CARTRIDGES

8.5 OTHERS

9 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS

9.1 OVERVIEW

9.2 ANTI-INFECTIVE’S

9.2.1 ANTIBIOTICS

9.2.1.1 Azithromycin

9.2.1.2 Doxycycline

9.2.1.3 Vancomycin

9.2.1.4 Polymyxin B

9.2.1.5 Piperacillin

9.2.1.6 Tazobactam

9.2.1.7 Others

9.2.2 ANTIFUNGAL

9.2.2.1 Mycamine

9.2.2.2 Caspofungin Acetate

9.2.2.3 Isavuconazonium Sulfate

9.2.2.4 Amphotericin

9.2.2.5 Others

9.2.3 ANTIVIRAL

9.2.3.1 Acyclovir

9.2.3.2 Ganciclovir

9.2.3.3 Remdesivir

9.2.3.4 Others

9.2.4 OTHERS

9.3 ANTINEOPLASTIC

9.3.1 METHOTREXATE

9.3.2 GEMCITABINE

9.3.3 CYTARABINE

9.3.4 FLUDARABINE

9.3.5 DOXORUBICIN

9.3.6 OXALIPLATIN

9.3.7 ZOLEDRONIC ACID

9.3.8 OTHERS

9.4 DIURETICS

9.4.1 CHLOROTHIAZIDE

9.4.2 ETHACRYNIC ACID

9.4.3 ACETAZOLAMIDE

9.4.4 OTHERS

9.5 PROTON PUMP INHIBITOR

9.5.1 ESOMEPRAZOLE SODIUM

9.5.2 PANTOPRAZOLE SODIUM

9.5.3 OMEPRAZOLE

9.5.4 OTHERS

9.6 ANESTHETIC

9.6.1 VECURONIUM BROMIDE

9.6.2 SODIUM THIOPENTAL

9.6.3 LIDOCAINE

9.6.4 OTHERS

9.7 ANTICOAGULANT

9.7.1 COUMADIN

9.7.2 UROKINASE

9.7.3 ANTITHROMBIN (RECOMBINANT)

9.7.4 APIXABAN

9.7.5 RIVAROXABAN

9.7.6 OTHERS

9.8 NSAID’S

9.8.1 INDOMETHACIN

9.8.2 IBUPROFEN

9.8.3 DICLOFENAC

9.8.4 KETOROLAC

9.8.5 OTHERS

9.9 CORTICOSTEROIDS

9.9.1 HYDROCORTISONE

9.9.2 METHYLPREDNISOLONE

9.9.3 OTHERS

9.1 OTHERS

10 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM

10.1 OVERVIEW

10.2 POWDER

10.3 LIQUID

11 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION

11.1 OVERVIEW

11.2 ONCOLOGY

11.3 AUTOIMMUNE DISEASES

11.4 HORMONAL DISORDERS

11.5 RESPIRATORY DISEASES

11.6 GASTROINTESTINAL DISORDERS

11.7 DERMATOLOGICAL DISORDERS

11.8 OPHTHALMIC DISEASES

11.9 OTHERS

12 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 INTRAVENOUS/INFUSION

12.3 INTRAMUSCULAR

12.4 OTHERS

13 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDERS

14.3 RETAIL SALES

14.4 OTHERS

14.5 OVERVIEW

15 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY

15.1 EUROPE

15.1.1 GERMANY

15.1.2 FRANCE

15.1.3 U.K.

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 NETHERLANDS

15.1.7 RUSSIA

15.1.8 SWITZERLAND

15.1.9 TURKEY

15.1.10 AUSTRIA

15.1.11 NORWAY

15.1.12 HUNGARY

15.1.13 LITHUANIA

15.1.14 IRELAND

15.1.15 POLAND

15.1.16 REST OF EUROPE

16 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PFIZER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENT

18.2 FRESENIUS KABI LTD (A SUBSIDIARY OF FRESENIUS KABI AG)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENTS

18.3 CIPLA INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 NOVARTIS AG

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENT

18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 BAXTER

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 AMNEAL PHARMACEUTICALS LLC

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 ARISTOPHARMA LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 CELON LABORATORIES PVT.LTD.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 CIRONDRUGS

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 GENEX PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 GILEAD SCIENCES, INC.

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 OTSUKA PHARMACEUTICALS CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.)

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 SANOFI

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 VIATRIS INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

LIST OF TABLES 

TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS

TABLE 2 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 3 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 4 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 5 EUROPE ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 6 EUROPE ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 7 EUROPE ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 8 EUROPE ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 9 EUROPE ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 10 EUROPE DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 11 EUROPE PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 12 EUROPE ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 13 EUROPE ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 14 EUROPE NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 15 EUROPE CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 16 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 17 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 18 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 19 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 21 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 22 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 23 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 24 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 25 EUROPE ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 26 EUROPE ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 27 EUROPE ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 28 EUROPE ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 29 EUROPE ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 30 EUROPE DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 31 EUROPE PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 32 EUROPE ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 33 EUROPE ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 34 EUROPE NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 35 EUROPE CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 36 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 37 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 38 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 39 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 40 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 41 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 42 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 43 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 44 GERMANY ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 45 GERMANY ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 46 GERMANY ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 47 GERMANY ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 48 GERMANY ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 49 GERMANY DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 50 GERMANY PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 51 GERMANY ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 52 GERMANY ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 53 GERMANY NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 54 GERMANY CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 55 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 56 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 57 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 58 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 59 GERMANY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 60 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 61 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 62 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 63 FRANCE ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 64 FRANCE ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 65 FRANCE ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 66 FRANCE ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 67 FRANCE ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 68 FRANCE DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 69 FRANCE PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 70 FRANCE ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 71 FRANCE ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 72 FRANCE NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 73 FRANCE CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 74 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 75 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 76 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 77 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 78 FRANCE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 79 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 80 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 81 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 82 U.K. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 83 U.K. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 84 U.K. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 85 U.K. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 86 U.K. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 87 U.K. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 88 U.K. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 89 U.K. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 90 U.K. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 91 U.K. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 92 U.K. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 93 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 94 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 95 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 97 U.K. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 98 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 99 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 100 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 101 ITALY ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 102 ITALY ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 103 ITALY ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 104 ITALY ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 105 ITALY ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 106 ITALY DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 107 ITALY PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 108 ITALY ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 109 ITALY ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 110 ITALY NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 111 ITALY CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 112 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 113 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 114 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 115 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 116 ITALY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 117 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 118 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 119 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 120 SPAIN ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 121 SPAIN ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 122 SPAIN ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 123 SPAIN ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 124 SPAIN ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 125 SPAIN DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 126 SPAIN PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 127 SPAIN ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 128 SPAIN ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 129 SPAIN NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 130 SPAIN CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 131 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 132 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 133 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 134 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 135 SPAIN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 136 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 137 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 138 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 139 NETHERLANDS ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 140 NETHERLANDS ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 141 NETHERLANDS ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 142 NETHERLANDS ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 143 NETHERLANDS ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 144 NETHERLANDS DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 145 NETHERLANDS PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 146 NETHERLANDS ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 147 NETHERLANDS ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 148 NETHERLANDS NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 149 NETHERLANDS CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 150 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 151 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 152 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 153 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 154 NETHERLANDS LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 155 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 156 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 157 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 158 RUSSIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 159 RUSSIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 160 RUSSIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 161 RUSSIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 162 RUSSIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 163 RUSSIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 164 RUSSIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 165 RUSSIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 166 RUSSIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 167 RUSSIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 168 RUSSIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 169 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 170 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 171 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 172 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 173 RUSSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 174 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 175 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 176 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 177 SWITZERLAND ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 178 SWITZERLAND ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 179 SWITZERLAND ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 180 SWITZERLAND ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 181 SWITZERLAND ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 182 SWITZERLAND DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 183 SWITZERLAND PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 184 SWITZERLAND ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 185 SWITZERLAND ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 186 SWITZERLAND NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 187 SWITZERLAND CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 188 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 189 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 190 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 191 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 192 SWITZERLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 193 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 194 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 195 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 196 TURKEY ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 197 TURKEY ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 198 TURKEY ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 199 TURKEY ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 200 TURKEY ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 201 TURKEY DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 202 TURKEY PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 203 TURKEY ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 204 TURKEY ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 205 TURKEY NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 206 TURKEY CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 207 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 208 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 209 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 210 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 211 TURKEY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 212 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 213 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 214 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 215 AUSTRIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 216 AUSTRIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 217 AUSTRIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 218 AUSTRIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 219 AUSTRIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 220 AUSTRIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 221 AUSTRIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 222 AUSTRIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 223 AUSTRIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 224 AUSTRIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 225 AUSTRIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 226 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 227 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 228 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 229 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 230 AUSTRIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 231 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 232 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 233 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 234 NORWAY ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 235 NORWAY ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 236 NORWAY ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 237 NORWAY ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 238 NORWAY ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 239 NORWAY DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 240 NORWAY PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 241 NORWAY ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 242 NORWAY ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 243 NORWAY NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 244 NORWAY CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 245 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 246 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 247 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 248 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 249 NORWAY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 250 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 251 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 252 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 253 HUNGARY ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 254 HUNGARY ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 255 HUNGARY ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 256 HUNGARY ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 257 HUNGARY ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 258 HUNGARY DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 259 HUNGARY PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 260 HUNGARY ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 261 HUNGARY ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 262 HUNGARY NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 263 HUNGARY CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 264 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 265 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 266 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 267 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 268 HUNGARY LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 269 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 270 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 271 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 272 LITHUANIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 273 LITHUANIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 274 LITHUANIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 275 LITHUANIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 276 LITHUANIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 277 LITHUANIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 278 LITHUANIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 279 LITHUANIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 280 LITHUANIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 281 LITHUANIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 282 LITHUANIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 283 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 284 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 285 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 286 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 287 LITHUANIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 288 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 289 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 290 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 291 IRELAND ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 292 IRELAND ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 293 IRELAND ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 294 IRELAND ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 295 IRELAND ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 296 IRELAND DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 297 IRELAND PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 298 IRELAND ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 299 IRELAND ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 300 IRELAND NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 301 IRELAND CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 302 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 303 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 304 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 305 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 306 IRELAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 307 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 308 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 309 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 310 POLAND ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 311 POLAND ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 312 POLAND ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 313 POLAND ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 314 POLAND ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 315 POLAND DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 316 POLAND PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 317 POLAND ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 318 POLAND ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 319 POLAND NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 320 POLAND CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 321 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 322 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 323 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 324 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 325 POLAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 326 REST OF EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES 

FIGURE 1 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET

FIGURE 15 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020

FIGURE 16 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)

FIGURE 17 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)

FIGURE 18 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 19 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020

FIGURE 20 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)

FIGURE 21 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)

FIGURE 22 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 23 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020

FIGURE 24 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)

FIGURE 25 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)

FIGURE 26 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE

FIGURE 27 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020

FIGURE 28 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 29 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 30 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 31 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 33 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 36 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 37 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 38 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 40 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 41 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 42 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 44 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 45 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY TYPE (2021-2028)

FIGURE 48 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES 

FIGURE 1 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET

FIGURE 15 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020

FIGURE 16 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)

FIGURE 17 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)

FIGURE 18 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 19 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020

FIGURE 20 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)

FIGURE 21 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)

FIGURE 22 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 23 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020

FIGURE 24 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)

FIGURE 25 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)

FIGURE 26 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE

FIGURE 27 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020

FIGURE 28 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 29 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 30 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 31 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 33 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 34 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 36 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 37 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 38 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 40 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 41 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 42 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 44 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 45 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 46 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 47 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: BY TYPE (2021-2028)

FIGURE 48 EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19